Literature DB >> 8641968

p53 accumulation in colorectal cancer with hepatic metastasis.

K Maruyama1, T Tanaka, S Baba, S Nakamura, Y Endo, H Sugimura.   

Abstract

The prevalence of immunoreactive p53 and argyrophilic nucleolar organizer region (AgNOR) numbers were compared between colorectal cancers with (n=44) and without (n=51) hepatic metastasis for at least 5 years. At the same time, the distribution of p53-positive cells in primary, metastatic, and xenografted tumors from the same individuals were studied. Overall, p53 positivity was found more frequently in the cases with hepatic metastasis than in non-metastatic controls, regardless of the distribution pattern (P<0.05), whereas AgNOR counts were not different between the two groups. Significant heterogeneity in the distribution of p53 immunoreactivity was noted in both the primary and metastatic lesions. The intratumor distribution patterns of p53 immunoreactive cells in the primary (n=33), metastatic (n=33), and xenografted (n=7) tumors of the same individuals were consistent in the majority of cases. There were a few cases in which the p53 immunoreactive cells were more dominant in the metastatic tumor cells. Our observations suggest that p53 accumulation in colorectal cancer is associated with increased risk for hepatic metastasis, while cell proliferation as represented by AgNOR numbers is not. In addition, heterogeneity of abnormal p53 accumulation in the tumor is maintained during the course of metastasis and even after implantation in nude mouse. p53-Immunoreactive cells in the population of colorectal cancer cells do not necessarily have higher metastasizing potential.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641968      PMCID: PMC5921109          DOI: 10.1111/j.1349-7006.1996.tb00232.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  34 in total

1.  Argyrophilic nucleolar organizer regions in breast cancer: prognostic significance.

Authors:  Z Kolár; T Zábranský; K Mattler; E Zábranský
Journal:  Cesk Patol       Date:  1992-09

Review 2.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

3.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Authors:  B Vojtĕsek; J Bártek; C A Midgley; D P Lane
Journal:  J Immunol Methods       Date:  1992-07-06       Impact factor: 2.303

4.  Prognostic significance of argyrophilic nucleolar organizer regions in esophageal carcinoma.

Authors:  M Morita; H Kuwano; H Matsuda; S Moriguchi; K Sugimachi
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

5.  Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance.

Authors:  H Tomoda; Y Kakeji
Journal:  J Surg Oncol       Date:  1995-02       Impact factor: 3.454

6.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Authors:  A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

7.  Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential.

Authors:  H Iino; M Fukayama; Y Maeda; M Koike; T Mori; T Takahashi; R Kikuchi-Yanoshita; M Miyaki; S Mizuno; S Watanabe
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

8.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

9.  Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes.

Authors:  Y Kakeji; D Korenaga; S Tsujitani; H Baba; H Anai; Y Maehara; K Sugimachi
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

10.  Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma.

Authors:  J W Mulder; I O Baas; M M Polak; S N Goodman; G J Offerhaus
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

View more
  2 in total

1.  Immunophenotyping of human HT29 colon cancer cell primary tumours and their metastases in severe combined immunodeficient mice.

Authors:  B S Mitchell; H P Horny; U Schumacher
Journal:  Histochem J       Date:  1997-05

2.  Heterogeneity of p53 mutational status in intramucosal carcinoma of the colorectum.

Authors:  S Yamada; Y Ajioka; H Watanabe; H Hashidate; H Takaku; S Kazama; J Yokoyama; K Nishikura; T Fujiwara; H Asakura
Journal:  Jpn J Cancer Res       Date:  2001-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.